Clinical Trials Arena Highlights MDL-001’s Preclinical Potential Across Multiple Viral Infections
Press Coverage
Patrick ONeill
Clinical Trials Arena highlights MDL-001’s reported preclinical activity across respiratory, hepatic, and gastrointestinal viral families, positioning the program as a differentiated broad-spectrum antiviral candidate.
Patrick ONeill
Head of Partnerships and Investor Relations
Clinical Trials Arena reported on Model Medicines’ MDL-001 following an update presented at the Biocom Global Partnering Conference in California. The article describes MDL-001 as a potential broad-spectrum oral antiviral, citing reported preclinical activity across RSV, influenza, SARS-CoV-2, HCV, HBV, HDV, and norovirus. It also discusses comparative preclinical analyses against established antivirals, including remdesivir, sofosbuvir, and nirmatrelvir, while framing MDL-001’s breadth of activity as potentially relevant to chronic liver infections, respiratory outbreaks, early empiric treatment, pandemic preparedness, and government stockpiling strategies.
